The EPXH2 gene encodes soluble epoxide hydrolase (sEH), which has two distinct enzyme activities: epoxide hydrolase (Cterm-EH) and phosphatase (Nterm-phos). The Cterm-EH is involved in the metabolism of arachidonic acid epoxides that play important roles in blood pressure, cell growth, inflammation, and pain. While recent findings suggested complementary biological roles for Nterm-phos, research is limited by the lack of potent bioavailable inhibitors of this phosphatase activity. Also, a potent bioavailable inhibitor of this activity could be important in the development of therapy for cardiovascular diseases. We report herein the development of an HTS enzyme-based assay for Nterm-phos (Z 0 > 0.9) using AttoPhos as the substrate. This assay was used to screen a wide variety of chemical entities, including a library of known drugs that have reached through clinical evaluation (Pharmakon 1600), as well as a library of pesticides and environmental toxins. We discovered that ebselen inhibits sEH phosphatase activity. Ebselen binds to the N-terminal domain of sEH (K I = 550 nM) and chemically reacts with the enzyme to quickly and irreversibly inhibit Nterm-phos, and subsequently Cterm-EH, and thus represents a new class of sEH inhibitor.
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In mammals, The EPHX2 gene encodes the soluble epoxide hydrolase (sEH), a cytosolic enzyme ubiquitous in vertebrates [1] . While highly expressed in the liver, sEH is also expressed in other tissues including vascular endothelium, leukocytes, red blood cells, smooth muscle cells, adipocytes, and the proximal tubule [1] [2] [3] . The sEH protein is a homodimer with a monomeric unit mass of 62.5 kDa [4] . Interestingly, sEH has two distinct activities in two separate structural domains of each monomer: the C-terminal epoxide hydrolase activity (Cterm-EH; EC 3.3.2.10) and the N-terminal phosphatase activity (Nterm-phos; EC 3.1.3.76) [4] . The Cterm-EH is responsible for the biological roles associated with sEH [1, 2, [5] [6] [7] , while a magnesium-dependent hydrolysis of phosphate esters is associated with the Nterm-phos [8, 9] . The Cterm-EH hydrolyzes epoxy-fatty acids such as epoxyeicosatrienoic acids that are potent endogenous signaling molecules [10] . Through the development of potent selective inhibitors, we demonstrated the Cterm-EH to be a novel pharmacological target to treat hypertension, inflammation, and pain in animal models [5] [6] [7] 11] , Pharmacological inhibition of Cterm-EH has resulted in anti-inflammatory [5, 6] , anti-hypertensive [12, 13] , neuroprotective [14] , and cardioprotective effects [5] .
Although the role of the Nterm-phos activity is not known, recent findings suggest a biological role. The sEH-null mice that lack both Cterm-EH and Nterm-phos activities have lower cholesterol and steroid levels [15] . Furthermore, in recombinant HepG2 cells, Cterm-EH activity lowered cholesterol synthesis while Nterm-phos activity increased it [16] . Taken together, these data suggest that sEH regulates cholesterol levels in vivo and in vitro and that the Nterm-phos is a potential therapeutic target in hypercholesterolemia-related disorders. Similarly, in recombinant endothelial cells, both Cterm-EH and Nterm-phos activities contribute to growth factor expression and cell growth [17] . In mice, it seems that the Nterm-phos may play a role in the development of hypoxiainduced pulmonary hypertension [18] . The phosphatase activity of sEH was shown recently to play a pivotal role in the regulation of endothelial nitric oxide (NO) synthase activity and NO-mediated endothelial cell functions [19] . Human polymorphism studies have shown that the Arg287Gln polymorph of sEH is associated with the onset of coronary artery calcification in African-American subjects [20] and insulin resistance in type 2 diabetic patients [21] . This single-nucleotide polymorphism (SNP G860A) of sEH reduces both Cterm-EH and Nterm-phos activities [22, 23] . Furthermore, people having a Lys55Arg polymorphism of sEH, which has reduced Nterm-phos but increased Cterm-EH, have higher risk of coronary heart diseases. The presence of this SNP also increases the longterm risk of ischemic stroke in men [24] . In support of a role for Nterm-phos in these processes, sEH phosphatase activity was recently shown to represent a significant part of cellular lysophosphatidic acid hydrolysis in various tissues [25] .
Specific catalytic enzyme inhibitors are important research tools to help understand the mechanism of an enzyme and of pathologies that may be associated with dysfunctions of this enzyme. A potent bioavailable inhibitor of this activity could also be important as a potential therapeutic in some cardiovascular diseases. Because common commercial phosphatase inhibitors do not influence the Nterm-phos activity [9] , it is necessary to develop new phosphatase inhibitors for Nterm-phos as biochemical and physiological probes. We recently developed the first generation of Nterm-phos inhibitors. While sulfates were shown not to be Nterm-phos substrates [8] , we described sulfate, sulfonate, and phosphonate lipids as novel potent inhibitors of Nterm-phos [26] . These compounds are competitive inhibitors with inhibition constant (K I ) values in the low-micromolar range. They act by mimicking the binding of the phosphate substrate in the catalytic cavity [26] . Farnesyl derivatives were also shown to inhibit Nterm-phos in the micromolar range by chelating the catalytic magnesium ion [27, 28] . While these inhibitors are effective in vitro, they have limited efficacy in cell cultures, and they are completely inactive in vivo. These results highlight the need to improve the potency of Nterm-phos inhibitors as well as their availability. To achieve this goal, we report herein the development of an HTS assay for Nterm-phos and the screening of two chemical libraries containing a wide variety of chemical entities: a 176-synthetic-chemical library of mostly pesticides [29] and another library of 1600 known drugs from the U.S. and International Pharmacopeia (Pharmakon 1600).
Materials and methods

Materials
The environmental chemical library was prepared previously in the laboratory [29] . The Pharmakon 1600 library of chemicals was obtained from Microsource Discovery Systems (Gaylordsville, CT, USA). The AttoPhos substrate was obtained from Promega (Madison, WI, USA). All chemicals and solvents were obtained from Fisher Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich (St. Louis, MO, USA) and were used without further purification.
Enzyme preparations
Recombinant human sEH (HsEH) was produced in a baculovirus expression system [30] , and purified by affinity chromatography [31] . This enzyme preparation was at least 97% pure, based on SDS-PAGE followed by scanning densitometry. The enzyme preparation was kept at À80°C until usage. Protein concentration was quantified by using the Pierce BCA assay using fraction V bovine serum albumin (BSA) as the calibrating standard.
Optimization of assay conditions
To optimize enzyme and substrate concentrations, a checkerboard assay was carried out, which tested combinations of several final concentrations of substrate (AttoPhos, 12.5-100 lM) and serial dilutions of enzyme (HsEH, 1.6-105 nM, 0.02-1.31 lg/well, 200 ll/well) in BisTris-HCl buffer (25 mM, pH 7.0), containing 1 mM MgCl 2 and 0.1 mg/ml BSA (buffer A). BSA was used to stabilize the human sEH and to reduce nonspecific inhibition [29] . The progress of the reaction was followed by measuring the appearance of the fluorescent alcohol (k ex 435 nm, k em 555 nm, k cutoff 515 nm) using a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA) at room temperature (23°C) with reads every 3 min for 2 h. Each condition was done in triplicate.
Several chemicals and solvents were tested for their ability to stop the Nterm-phos enzymatic reaction for a fluorescence endpoint measurement setting. These chemicals and solvents were examined for their ability to prohibit enzyme reaction and substrate autohydrolysis, as well as to maintain the existing fluorescent signal. Reactions were conducted using optimized assay conditions ([E] final 2.1 nM; [S] final 25 lM). After a 60-min incubation at room temperature in the dark, 100 ll of stop solution was added to each well; buffer A was added in the control wells. After the addition of candidate stop solutions, we tested their efficacy at stopping the reaction and effects on the fluorescent signal strength and stability by measuring the fluorescence (k ex 435 nm, k em 555 nm, k cutoff 515 nm) every 5 min for 30 min at room temperature (23°C). Each condition was done in 16 replicates. Hydrolysis rates were determined by linear regression analyses employing the plate reader's software (SoftMax Pro 4.7). The signal-to-background ratio (S/B) was calculated by dividing the reaction average velocity in the presence of enzyme (Ave enz ) by the average background hydrolysis rate (Ave blank ). The signal-to-noise ratio (S/N) was calculated by dividing the reaction velocity in the presence of enzyme by the standard deviation of the background hydrolysis (SD blank ). The Z 0 factor was calculated following the method of Zhang et al. [32] using the formula
Assay validation for inhibition study, interplate variation, and accuracy
Assay validation for the endpoint assay system was performed. After 60 min incubation at room temperature in the dark, 100 ll of 0.1 M NaOH in water was added to each well. After strong mixing, the progress of the reaction was measured as described above. Measurement of three plates testing three inhibitors, in ABC, BCA, and CAB order, was repeated three times on three separate days, using different solutions of enzyme, inhibitors, and substrate each time.
Assay in 384-well plate
To a black polystyrene 384-well plate, 37.5 ll of buffer A was added to each well. One microliter of inhibitor solution in Me 2 SO was then added to 3 wells for each concentration (0. 25 lM). After 60 min incubation at room temperature in the dark, 100 ll of 0.1 M NaOH in water was added to each well.
After strong mixing, the amount of fluorescent alcohol produced was measured as described above. Compounds that gave more than 80% inhibition at 10 lM were selected as positive hits, because the fluorescent signal observed for them was not significantly different from the signal for 100% inhibition. For counterscreening, fresh solutions of all positive compounds were prepared in Me 2 SO. The IC 50 for each compound (i.e., the concentration of an inhibitor that inhibited 50% of the enzyme activity) was determined by measuring Nterm-phos activities in the absence and presence of increasing concentrations of inhibitor (0.1 < [I] < 10 lM) using AttoPhos as substrate in a kinetic setup as described [26] . IC 50 was calculated by nonlinear regression of at least five data points using SigmaPlot. Results are means ± standard deviation of at least three separate measurements.
Results and discussion
Optimization of HTS assay
AttoPhos was previously shown to be a good fluorescent substrate for sEH phosphatase activity [26] . Prior to using this substrate for a screening assay, we first tested the effects of enzyme and substrate concentrations and time on the assay performances. Although measurements were obtained for up to 120 min, at time = 60 min (a common HTS assay endpoint), we calculated for each condition the linearity of the reaction (r 2 ), the percentage of substrate turnover (%TO), the S/B, the S/N, and the Z 0 factor (Table 1 and Supplementary Fig. S1 ). Linear (r 2 > 0.99) increases in fluorescence were observed for [E] 66.6 nM, at all the [S] tested, and this increase stayed linear for up to 2 h (Fig. 1) The search for an appropriate stop solution was then carried out to increase flexibility of the fluorescence endpoint assay for Ntermphos. If it were possible to stop an ongoing substrate hydrolysis reaction and conserve the current signal, the endpoint assay could potentially be interrupted any time between 60 and 90 min after substrate addition. Most importantly, the quantification of the fluorescent signal could be achieved independent of the assay starting time, which would significantly improve the adaptability of the system. Three kinds of conditions were tested: addition of cosolvent to denature the enzyme (i.e., methanol, ethanol), addition of selective Nterm-phos inhibitor [26] , and change to a pH at which Nterm-phos is inactive. As seen in Table 2 , addition of methanol and ethanol reduced significantly the enzymatic hydrolysis rate as well as the fluorescence signal, thus decreasing the assay performance. The alkalization of the reaction with NaOH completely stopped the reaction at pH values above 10. Furthermore, the fluorescent signal was increased by an order of magnitude; this is probably due to the formation of the fluorescent phenolate ( Supplementary Fig. S2 ). It resulted in higher S/B and S/N ratios as well as higher Z 0 factors. As seen in Supplementary  Fig. S3 , the increase in fluorescence by 0.1 M NaOH is proportional (r 2 > 0.99) to the fluorescence resulting from the enzymatic activity at pH 7.0. Interestingly, the addition of a high concentration of SDS (10 mM), a low-nanomolar Nterm-phos inhibitor [26] , resulted in complete loss of the fluorescent signal. At such high concentrations, SDS forms micelles that could quench the fluorescent signal. 
Assay validation
To validate the assay, we first investigated its ability to differentiate between and classify known inhibitors of various potencies. The IC 50 values of previously characterized sEH inhibitors were determined employing the endpoint assay system described above. Using a kinetic assay [26] , dodecyl phosphate was found to be a better inhibitor than dodecyl sulfonate or dodecyl sulfate (Table 3) . In a second experiment, we tested the repeatability of the assay by measuring its accuracy and precision by measuring the inhibition of three inhibitors over several plates (three plates/day) and several days (3 days total). Overall, we found less than 5% variation in the assay performance (Table 3 ). For inhibition above 20%, we obtained accuracy above 95% and a variation in precision under 5%. This results in less than 10% variation in the calculated IC 50 . Results for each day were very similar. When looking at the difference in signal between inhibited and uninhibited enzyme samples, a significant separation of the signals (Z values >0.6) was obtained for inhibition below 80% (Supplementary Fig. S4 ). Put together, these data indicate that the assay is highly reproducible and accurate, with a good separation and signal-to-noise ratio between inhibition of 20% and 80%. Accuracy decreased below 20%, and above 80% the signal was not statistically discernible from the background. Finally, we tested the performance of the assay in a 384-well format. As shown in Supplementary Table S1, overall, larger variations were obtained but the results obtained from 384-well plates were similar to those from 96-well plates in terms of assay performance (S/B, S/N, and Z 0 ) and ability to measure accurately inhibitor potency. The assay performance could probably be improved further by robotic addition of reagents.
Library screening
To test the ability of the assay to select new chemical entities that potently inhibit Nterm-phos, we first screened a small library of pesticides [29] at two final concentrations of the tested chemicals (1 and 10 lM). Overall, we obtained S/B = 170 ± 17, S/ N = 1180 ± 120, and Z 0 = 0.92 ± 0.02, indicating that the assay performed very well. Of 176 compounds, 3 compounds gave more than 50% inhibition at 10 lM and only 1 of them at 1 lM. This most potent compound was identified as dodecyl phosphoric acid, a known Nterm-phos inhibitor (see above) with an IC 50 of 2.2 ± 0.3 lM, confirming the ability of the assay to discriminate sEH phosphatase inhibitors, and to discover new structures that inhibit Nterm-phos, one should screen at 10 lM [33] . The potencies of the 2 other positive compounds, Folpet and Nabam, were tested using freshly made solutions. Nabam was found not to significantly inhibit Nterm-phos (IC 50 > 100 lM), while Folpet yielded an IC 50 of 25 ± 3 lM.
A library of 1600 commercial drugs was then screened at a final concentration of 10 lM, following the method described above.
Overall, we obtained on average for the 20 plates S/B = 55 ± 10, S/ N = 840 ± 210, and Z 0 = 0.92 ± 0.03, indicating that the assay performed very well. Of 1600 compounds, 24 (1.5%) inhibited Nterm-phos by over 50% at 10 lM, and 9 of these inhibited the enzyme by over 80% (Supplementary Fig. S5 ). The 24 compounds were retested, but using the AttoPhos assay in kinetic mode to eliminate compounds that affect the fluorescent signal. Only 6 compounds were found to give more than 80% inhibition. The potencies of these 6 positive compounds were then measured using freshly made solutions (Table 4) . Only 2 compounds (ebselen and sodium tetradecyl sulfate) were found to significantly inhibit Nterm-phos. Because sodium tetradecyl sulfate is a detergent, its inhibition of Nterm-phos could be due to a nonspecific promiscuous effect. However, sodium tetradecyl sulfate (STS) critical micelle concentration is around 2 mM [34] , roughly 100-fold higher than the concentrations at which we observed Nterm-phos. Thus, it is unlikely that Nterm-phos inhibition by STS is not specific. Furthermore, we previously showed that alkyl sulfates are competitive inhibitors of the sEH phosphatase activity [26] ; thus one could expect that sodium tetradecyl sulfate inhibits Nterm-phos in a similar fashion. On the other hand, ebselen represents a new class of potent sEH phosphatase inhibitor. To our knowledge, this is the second report of direct inhibition of a phosphatase by ebselen, the first being for a hog gastric phosphatase [35] . Because we found that it did not inhibit the human alkaline phosphatase, ebselen is probably not a general phosphatase inhibitor.
Selectivity, kinetic constants, and mechanism of ebselen inhibition
To test the selectivity of ebselen toward sEH phosphatase, we tested its ability to inhibit Cterm-EH activity as well as human microsomal EH, human alkaline phosphatase, and a series of esterases and amidases [26, 29] . Interestingly, we found that, in addition to Nterm-phos, ebselen also inhibits Cterm-EH but not the other enzymes tested. However, it does so with an IC 50 (2.2 ± 0.3 lM)
that is fivefold higher than that observed for Nterm-phos (Table 3) .
To test the hypothesis that ebselen inhibition of both activities of sEH is independent, we measured the effect of ebselen on both domains of sEH expressed separately [22, 26] . We found that 10 lM Table 4 Counterscreening of positive hits. ebselen for 5 min did not significantly inhibit the Cterm-EH expressed alone, while the Nterm-phos expressed alone was totally inhibited by the same treatment. This result suggests that ebselen interacts only with the N-terminal domain of sEH. Furthermore, we tested whether ebselen inhibition was reversible. After incubating 20 nM human sEH with 10 lM ebselen for 15 min, we dialyzed the enzyme to remove the small molecule. After exposure to the selenium-containing compound, we were not able to recover any of the Nterm-phos or Cterm-EH activities, suggesting that ebselen chemically reacts with the human sEH. Pretreatment of the enzyme with 5 mM glutathione before exposure to 10 lM ebselen for 5 min protected the human sEH activities. The addition of glutathione to the enzyme 5 min after exposure to ebselen did not permit the recovery of the Nterm-phos activity, but 30% of the Cterm-EH activity was recovered. Taken together, these results suggest a redox mechanism, which is not surprising since ebselen is used as an antioxidant [35, 36] . Interestingly, while Nterm-phos is stably and quickly inhibited by ebselen (less than a minute), Cterm-EH inhibition increases with time: its IC 50 decreased from 2.0 ± 0.3 to 0.85 ± 0.05 lM if the incubation time increased from 1 to 15 min. To support this observation we determined the kinetic constants of ebselen inhibition of Nterm-phos [26] and Cterm-EH [29] using a model of irreversible inhibition (Fig. 2 ) [38] . Interestingly, we observed similar dissociation constants (K I ) for both activities (Nterm-phos K I = 551 ± 6 nM, n = 3; Cterm-EH K I = 560 ± 10 nM, n = 3), while the first-order formation rate of the covalent enzyme-inhibitor complex (k i ) is around sevenfold faster for Nterm-phos (k i = 2.58 ± 0.05 min À1 , n = 3) than for Cterm-EH (k i = 0.39 ± 0.07 min
À1
, n = 3). Furthermore, sigmoidal curves were obtained for both activities (Fig. 2) , suggesting a cooperative or allosteric-like mechanism. Taken together these results suggest that ebselen chemically reacts with the N-terminal domain of the human sEH, rapidly inhibits Nterm-phos, and generates conformational changes leading to the slower denaturation of the enzyme and inhibition of Cterm-EH. In the mouse sEH, but not the human sEH, a cysteine residue, which is not in the active site, can allosterically inhibit the Cterm-EH activity when chemically modified [39] . More recently, the human sEH was shown to be redox regulated by 15-deoxy-D-prostaglandin, an electrophilic oxidant that dilates the coronary vasculature [40] . The results observed herein with ebselen are consistent with these previous observations.
In conclusion, we developed an excellent HTS assay for measuring the phosphatase activity of the human sEH that can be used to screen chemical libraries. The observed inhibition of HsEH by ebselen is intriguing. Because ebselen is an antioxidant drug that has numerous activities and targets [36, 37] , it is unlikely to be a monospecific Nterm-phos inhibitor in animals. Perhaps more importantly, the mode of action of ebselen suggests that the Nterminal domain of sEH contains an allosteric regulatory site for both of its catalytic activities. Nevertheless, it represents a lead for a new class of potent sEH phosphatase inhibitors that may provide valuable tools to investigate the biological role of the Ntermphos. Toward such a goal, one will need to characterize what adduct is formed on sEH in the presence of ebselen, as well as determining if mimics of glutathione peroxidases are a new class of sEH inhibitors or if it is more specific to selenium-containing antioxidants.
